Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Oculis Holding AGNASDAQ: OCS

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows in line with its trailing trend

Q1 FY2026 depreciation & amortization of CHF 157.43K rose 28.0% year over year, ahead of the +27.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.4% from the prior quarter. Over 3 fiscal years it compounded at +22.2% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +28.0% holds above the trailing-twelve-month pace of +27.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 157.43K-0.4% QoQ
Last fiscal yearDec 2025
CHF 546K+34.5% YoY
LTMMar 2026
CHF 580.43K+27.3% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.0%——
1 year+34.5%——
3-year CAGR+22.2%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

CHF · from the cash flow

Latest · FY2025
546K CHF
Year-over-year change
+34.5%
4-year CAGR
+23.5%

Depreciation & Amortization vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +27.3% is the 2nd highest of 6, against a peer median of +20.2%.
  • Depreciation & amortization amounts to 115.2% of revenue for OCS, versus a peer median of 20.5%.
OCS Competitors
Depreciation & Amortization for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HROWHarrow Health, Inc.LTM Mar 2026$20.35M USD+25.1%+75.1%7.6%
OCULOcular Therapeutix, Inc.LTM Mar 2026$4.63M USD+20.2%+27.0%8.9%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$2.45M USD+41.2%-1.9%32.1%
OCSOculis Holding AGLTM Mar 2026CHF 580.43K CHF+27.3%+22.2%115.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$119.64K USD+3.7%-17.0%35.9%
OKYOOKYO Pharma LimitedFY2025$2.56K USD-33.7%+3.2%—
Peer median (excluding OCS) —+20.2%+3.2%20.5%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(18.52M)(38.64M)(88.7M)(85.94M)(94.51M)
Depreciation & Amortization235K299K287K406K546K
Deferred Income Tax00000
Stock-Based Compensation328K804K3.61M9.78M16.04M
Change in Working Capital(791K)6M(12.99M)14.16M(70.67K)
Accounts Receivables233K(152K)36K247K1.9M
Inventory00000
Accounts Payables30K3.04M3.73M(1.71M)(1.86M)
Other Working Capital(1.05M)3.11M(16.76M)15.62M(106.97K)
Other Non-Cash Items4.93M6.47M43.95M14.09M15.77M
Operating Cash Flow(13.83M)(25.07M)(53.85M)(47.5M)(62.22M)
Capital Expenditures(28K)(3.55M)(48K)(230K)(287.47K)
Acquisitions (Net)00000
Purchases of Investments00(54.16M)(17.33M)(58.05M)
Sales of Investments00000
Other Investing Activities0(3.48M)000
Investing Cash Flow(28K)(3.55M)(54.21M)(17.56M)(59.38M)
Debt Repayment(98K)(159K)(158K)(274K)(373K)
Common Stock Issued00135.62M53.54M178.95M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(804K)(157K)(5.79M)763K16.77K
Financing Cash Flow55.19M1.71M129.67M54.03M178.6M
Effect of Forex Changes(16K)418K(3.08M)407K174.39K
Net Change in Cash41.33M(26.49M)18.54M(10.62M)57.17M
Free Cash Flow(13.85M)(28.62M)(53.89M)(47.73M)(62.51M)

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.